The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
The increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD). Although there is no standard therapy for NAFLD, previous reports support the effect of sodium-glucose...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/13/1/3 |
| _version_ | 1797471511675666432 |
|---|---|
| author | Takeshi Goya Koji Imoto Shigeki Tashiro Tomomi Aoyagi Motoi Takahashi Miho Kurokawa Hideo Suzuki Masatake Tanaka Masaki Kato Motoyuki Kohjima Yoshihiro Ogawa |
| author_facet | Takeshi Goya Koji Imoto Shigeki Tashiro Tomomi Aoyagi Motoi Takahashi Miho Kurokawa Hideo Suzuki Masatake Tanaka Masaki Kato Motoyuki Kohjima Yoshihiro Ogawa |
| author_sort | Takeshi Goya |
| collection | DOAJ |
| description | The increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD). Although there is no standard therapy for NAFLD, previous reports support the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on NAFLD. Recently, fatty liver disease with metabolic dysfunction was proposed to be defined as a novel concept, “metabolic associated fatty liver disease (MAFLD)”, and it was proposed that new criteria for MAFLD diagnosis be established. To clarify the effect of SGLT2 inhibitors on MAFLD, we analyzed the efficacy of tofogliflozin in patients with MAFLD. We conducted a single-center, retrospective study to evaluate the efficacy of tofogliflozin in patients with MAFLD treated at Kyushu University Hospital between 2017 and 2019. Tofogliflozin was used to treat 18 patients with MAFLD. To determine the efficacy of tofogliflozin, we evaluated glucose metabolism, insulin resistance, liver injury, hepatic steatosis, and body composition three and six months after drug initiation. Although our study was a preliminary study because of some limitations (e.g., retrospective, observational, single-arm study, small sample size), we show that tofogliflozin could improve liver injury in patients with MAFLD by improving glucose metabolism and insulin resistance without causing muscle loss. |
| first_indexed | 2024-03-09T19:49:20Z |
| format | Article |
| id | doaj.art-82a8c35dab504599ab35d0af0bad627c |
| institution | Directory Open Access Journal |
| issn | 2036-7414 2036-7422 |
| language | English |
| last_indexed | 2024-03-09T19:49:20Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj.art-82a8c35dab504599ab35d0af0bad627c2023-11-24T01:15:52ZengMDPI AGGastroenterology Insights2036-74142036-74222022-01-01131202610.3390/gastroent13010003The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver DiseaseTakeshi Goya0Koji Imoto1Shigeki Tashiro2Tomomi Aoyagi3Motoi Takahashi4Miho Kurokawa5Hideo Suzuki6Masatake Tanaka7Masaki Kato8Motoyuki Kohjima9Yoshihiro Ogawa10Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanThe increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD). Although there is no standard therapy for NAFLD, previous reports support the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on NAFLD. Recently, fatty liver disease with metabolic dysfunction was proposed to be defined as a novel concept, “metabolic associated fatty liver disease (MAFLD)”, and it was proposed that new criteria for MAFLD diagnosis be established. To clarify the effect of SGLT2 inhibitors on MAFLD, we analyzed the efficacy of tofogliflozin in patients with MAFLD. We conducted a single-center, retrospective study to evaluate the efficacy of tofogliflozin in patients with MAFLD treated at Kyushu University Hospital between 2017 and 2019. Tofogliflozin was used to treat 18 patients with MAFLD. To determine the efficacy of tofogliflozin, we evaluated glucose metabolism, insulin resistance, liver injury, hepatic steatosis, and body composition three and six months after drug initiation. Although our study was a preliminary study because of some limitations (e.g., retrospective, observational, single-arm study, small sample size), we show that tofogliflozin could improve liver injury in patients with MAFLD by improving glucose metabolism and insulin resistance without causing muscle loss.https://www.mdpi.com/2036-7422/13/1/3MAFLDfatty liverSGLT2 inhibitortype 2 diabetes mellitusbody composition |
| spellingShingle | Takeshi Goya Koji Imoto Shigeki Tashiro Tomomi Aoyagi Motoi Takahashi Miho Kurokawa Hideo Suzuki Masatake Tanaka Masaki Kato Motoyuki Kohjima Yoshihiro Ogawa The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease Gastroenterology Insights MAFLD fatty liver SGLT2 inhibitor type 2 diabetes mellitus body composition |
| title | The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease |
| title_full | The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease |
| title_fullStr | The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease |
| title_full_unstemmed | The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease |
| title_short | The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease |
| title_sort | efficacy of tofogliflozin on metabolic dysfunction associated fatty liver disease |
| topic | MAFLD fatty liver SGLT2 inhibitor type 2 diabetes mellitus body composition |
| url | https://www.mdpi.com/2036-7422/13/1/3 |
| work_keys_str_mv | AT takeshigoya theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT kojiimoto theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT shigekitashiro theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT tomomiaoyagi theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT motoitakahashi theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT mihokurokawa theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT hideosuzuki theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT masataketanaka theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT masakikato theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT motoyukikohjima theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT yoshihiroogawa theefficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT takeshigoya efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT kojiimoto efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT shigekitashiro efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT tomomiaoyagi efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT motoitakahashi efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT mihokurokawa efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT hideosuzuki efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT masataketanaka efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT masakikato efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT motoyukikohjima efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease AT yoshihiroogawa efficacyoftofogliflozinonmetabolicdysfunctionassociatedfattyliverdisease |